Department of Medicine, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Cell Stem Cell. 2012 Jan 6;10(1):16-28. doi: 10.1016/j.stem.2011.12.013.
Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.
心血管疾病是全球范围内主要的致死原因。由于心脏组织的再生能力有限，人们已经开发出了多种方法，以便在体外和体内生成新的心肌细胞。除了用于细胞替代疗法，患者特异性心肌细胞还可能在药物测试、药物发现和疾病建模中找到应用。最近，生成心肌细胞的方法已经扩展到包括三种主要的起始细胞来源：人多能干细胞（hPSCs）、成年心脏来源的心肌祖细胞（CPCs）和重编程成纤维细胞。我们讨论了从 hPSCs 和重编程成纤维细胞生成新的心肌细胞的最新方法，强调了潜在的应用和未来的挑战。
